GS-4528 / Gilead - LARVOL DELTA

Study of GS-4528 in Adults With Solid Tumors (clinicaltrials.gov) - P1 | N=182 | Active, not recruiting | Sponsor: Gilead Sciences | Trial completion date: Dec 2025 ➔ Jul 2026 | Trial primary completion date: Dec 2025 ➔ Jul 2026

Monotherapy • Trial completion date • Trial primary completion date • Solid Tumor

Machine learning-based identification of core regulatory genes in hepatocellular carcinoma: insights from lactylation modification and liver regeneration-related genes. (PubMed, Front Oncol) - "We integrated lactylation modification profiles with transcriptomic data from three murine liver regeneration datasets (GSE20426, GSE70593, GSE4528)...This work uniquely establishes lactylation as a metabolic-epigenetic bridge linking physiological regenerative pathways to oncogenesis. By leveraging liver regeneration models and machine learning, we propose the identified gene panel as dual-purpose biomarkers for HCC diagnosis and therapeutic targeting, offering new insights into the metabolic-epigenetic regulation of HCC."

Journal • Hepatocellular Cancer • Oncology • Solid Tumor • CCNA2 • CD8 • KIF2C • RACGAP1

Study of GS-4528 in Adults With Solid Tumors (clinicaltrials.gov) - P1 | N=182 | Active, not recruiting | Sponsor: Gilead Sciences | Recruiting ➔ Active, not recruiting

Enrollment closed • Monotherapy • Solid Tumor

Study of GS-4528 in Adults With Solid Tumors (clinicaltrials.gov) - P1 | N=182 | Recruiting | Sponsor: Gilead Sciences | N=132 ➔ 182

Combination therapy • Enrollment change • Metastases • Monotherapy • Oncology • Solid Tumor

Study of GS-4528 in Adults With Solid Tumors (clinicaltrials.gov) - P1 | N=132 | Recruiting | Sponsor: Gilead Sciences | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Monotherapy • Oncology • Solid Tumor

Study of GS-4528 in Adults With Solid Tumors (clinicaltrials.gov) - P1 | N=132 | Not yet recruiting | Sponsor: Gilead Sciences

New P1 trial • Oncology • Solid Tumor